Marshall  Fordyce net worth and biography

Marshall Fordyce Biography and Net Worth

Founder of Vera Therapeutics

Dr. Fordyce brings more than 15 years’ experience leading teams in drug discovery, development, clinical translation, and commercialization of new treatments.

Before founding Vera, Fordyce was the founder and CEO of gene-editing company Trucode Gene Repair, Inc., having previously served as an entrepreneur in residence at Kleiner Perkins Caufield and Byers.

Earlier in his career, Fordyce served as Senior Director of clinical research at Gilead Sciences, Inc., where he contributed to seven new drug approvals and served as project lead for Gilead’s TAF/GENVOYA development program.

With subspecialty training in infectious disease from Columbia University Vagelos College of Physicians and Surgeons, Fordyce was previously Chief Resident at NYU Bellevue and spent two years as a translational research fellow at Rockefeller University.

Fordyce currently serves on the Board of Directors of the Albert and Mary Lasker Foundation. He received his BA from Harvard University and his MD from Harvard Medical School.

How old is Marshall Fordyce?

Dr. Fordyce is currently 49 years old. There are 5 older executives and no younger executives at Vera Therapeutics. The oldest executive at Vera Therapeutics is Dr. Robert M. Brenner M.D., Chief Medical Officer, who is 56 years old. Learn More on Marshall Fordyce's age.

How do I contact Marshall Fordyce?

The corporate mailing address for Dr. Fordyce and other Vera Therapeutics executives is , , . Vera Therapeutics can also be reached via phone at 650-770-0077 and via email at [email protected]. Learn More on Marshall Fordyce's contact information.

Has Marshall Fordyce been buying or selling shares of Vera Therapeutics?

Marshall Fordyce has not been actively trading shares of Vera Therapeutics during the last ninety days. Learn More on Marshall Fordyce's trading history.

Who are Vera Therapeutics' active insiders?

Vera Therapeutics' insider roster includes Marshall Fordyce (Founder), Marshall Fordyce (CEO and Founder), Sean Grant (CFO), and Joseph Young (CAO). Learn More on Vera Therapeutics' active insiders.

Are insiders buying or selling shares of Vera Therapeutics?

In the last year, Vera Therapeutics insiders bought shares 1 times. They purchased a total of 161,290 shares worth more than $4,999,990.00. In the last year, insiders at the sold shares 12 times. They sold a total of 1,680,949 shares worth more than $44,809,507.61. The most recent insider tranaction occured on October, 28th when Director Beth C Seidenberg sold 15,000 shares worth more than $720,450.00. Insiders at Vera Therapeutics own 21.7% of the company. Learn More about insider trades at Vera Therapeutics.

Information on this page was last updated on 10/28/2024.

Marshall Fordyce Insider Trading History at Vera Therapeutics

See Full Table

Marshall Fordyce Buying and Selling Activity at Vera Therapeutics

This chart shows Dr. Marshall Fordyce's buying and selling at Vera Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Vera Therapeutics Company Overview

Vera Therapeutics logo
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.
Read More

Today's Range

Now: $48.31
Low: $47.10
High: $48.94

50 Day Range

MA: $43.47
Low: $38.64
High: $49.43

2 Week Range

Now: $48.31
Low: $12.28
High: $51.61

Volume

793,048 shs

Average Volume

1,160,098 shs

Market Capitalization

$3.06 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.03